GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 401–500 of 880
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
“In the kidney, GLP-1 receptors are located at the afferent arteriole [63] and proximal tubule [64], which leads to divergent acute effects”
BackgroundClinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 29
Sakamoto, K., Kuno, K., Takemoto, M., He, P. C., Ishikawa, T., Onishi, S., Ishibashi, R., Okabe, E., Shoji, M., Hattori, A., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2015/727152 · Cited by 21
Katsuda, Y., Ohta, T., Shinohara, M., Tong, B., & Yamada, T. (2013) · Open Journal of Animal Sciences · doi:10.4236/ojas.2013.34050 · Cited by 27
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Nielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 22
Rashid, Z., Woldesenbet, S., Khalil, M., Iyer, S., Khan, M. M. M., Altaf, A., Munir, M. M., Catalano, G., Mumtaz, K., & Pawlik, T. M. (2024) · Liver International · doi:10.1111/liv.16132 · Cited by 25
“There is prior evidence that GLP-1RA has the potential to enhance and possibly reverse diabetic nephropathy by affecting the renin–angiotensin–aldosterone axis (RAAS) [40].”
Mechanisms and pharmacotherapy of cancer cachexia‐associated anorexia
Sato, R., da Fonseca, G. W. P., das Neves, W., & von Haehling, S. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70031 · Cited by 25
“65 GLP-1 analogs that mimic the action of this incretin hormone have been shown to pro - duce significant weight loss through mechanisms such as prolonging gastric emptying, 66 promoting satiety, 67 and increasing energy expen - diture by brown remodeling of white adipose tissue and lipolysis.”
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 31
“GLP-1 receptors are expressed in various tissues, including the hypothalamus, pancreas, smooth muscle, adipose tissue, kidneys, heart and lungs (37).”
Siddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
“This rise in cAMP can increase heart rate and predispose to cardiomyocyte necrosis, worsening heart failure outcomes [33, 34].”
Marques, P. S., Travlos, C. K., Matias, P., Neves, J. S., Tsoukas, M. A., Mavrakanas, T. A., Joza, J. E., Ferreira, J. P., & Sharma, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102573 · Cited by 22
Glucagon-like peptide-1, a matter of taste?
Jensterle, M., DeVries, J. H., Battelino, T., Battelino, S., Yıldız, B. O., & Janež, A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09609-x · Cited by 25
“It was demonstrated that endogenous GLP1 and administration of GLP1RA affect CNS activation in response to viewing pictures of food items [86, 87], which is related to the predictive value of food consumption and craving for food.”
BackgroundGlucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Jensen, D. M., Skovsted, G. F., Bonde, M. F. B., Bentzon, J. F., Rolin, B., Franck, G., Ougaard, M. K., Voetmann, L. M., Bachmann, J. C., Uryga, A., et al. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.004 · Cited by 21
Self-citationThe Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell
Brubaker, P. L. (2022) · Endocrinology · doi:10.1210/endocr/bqac159 · Cited by 24
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
Madonna, R., Biondi, F., Ghelardoni, S., D'Alleva, A., Quarta, S., & Massaro, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.030 · Cited by 24
Singh, T. P., Vangaveti, V., & Malabu, U. H. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.005 · Cited by 19
“Diab Met Syndr: Clin Res Rev (2015), htt However, the observation that GLP-1 receptor activity augments myocardial function, anti-inflammatory mechanisms and offers cardioprotection and vasoprotection highlights the need for further studies [8].”
BackgroundGiblett, J. P., Axell, R. G., White, P. A., Clarke, S. J., McCormick, L., Read, P. A., Reinhold, J., Brown, A. J., O’Sullivan, M., West, N. E. J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0416-3 · Cited by 22
“Studies have suggested that, in the human heart, the GLP-1 receptor is only present in the sinoatrial node [28].”
BackgroundChicken Intestinal L Cells and Glucagon-like Peptide-1 Secretion
Hiramatsu, K. (2019) · The Journal of Poultry Science · doi:10.2141/jpsa.0190003 · Cited by 23
“However, this hormone mainly acts as an incretin hormone (Drucker, 2006); the receptor that specifically binds to GLP-1 is located on the pancreatic B cell, which is known to secrete insulin in mammals (Hörsch et al., 1997; Tornehave et al., 2008; Pyke et al., 2014).”
BackgroundWahba, N. S., Abdel-Ghany, R. H., Ghareib, S. A., Abdel-Aal, M., & Alsemeh, A. E. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105196 · Cited by 20
Spatiotemporal control of GLP-1 receptor activity
Manchanda, Y., Bitsi, S., Kang, Y., Jones, B. J., & Tomás, A. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.07.003 · Cited by 23
Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4
Lee, S. J., Diener, K., Kaufman, S., Krieger, J.-P., Pettersen, K. G., Jejelava, N., Arnold, M., Watts, A. G., & Langhans, W. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.008 · Cited by 20
Chen, H., Liu, S., Gao, S. H., Shi, H., Yan, Y., Xu, Y., Fang, J., Wang, W., Chen, H., & Liu, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-01206-9 · Cited by 39
Li, J., Rawson, J., Chea, J., Tang, W., MIAO, L. N., Sui, F., Li, C., Poku, E. K., Shively, J. E., & KANDEEL, F. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-42172-3 · Cited by 20
Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease
Ougaard, M. E., Sembach, F. E., Jensen, H. E., Pyke, C., Knudsen, L. B., & Kvist, P. H. (2020) · Nephron · doi:10.1159/000509418 · Cited by 19
Self-citationNESTOR, J. J. J., Zhang, X., Jaw‐Tsai, S., Parkes, D. G., & Becker, C. (2021) · Peptide Science · doi:10.1002/pep2.24221 · Cited by 24
Liu, X., Patel, K. P., & Zheng, H. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022542 · Cited by 21
Punjabi, M., Kosareva, A., Xu, L., Ochoa‐Espinosa, A., Decembrini, S., Hofmann, G., Wyttenbach, S., Rolin, B., Nyberg, M., & Kaufmann, B. A. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.08.002 · Cited by 26
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1
Gastaldelli, A., Gaggini, M., & DeFronzo, R. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000384 · Cited by 19
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., et al. (2024) · Medicine · doi:10.1097/md.0000000000040364 · Cited by 37
Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Model, J. F. A., Normann, R. S., Vogt, É. L., Dentz, M. C. V., de Amaral, M., Xu, R., Bachvaroff, T. R., Spritzer, P. M., Chung, J. S., & Vinagre, A. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116623 · Cited by 22
Quantifying antibody binding: techniques and therapeutic implications
Lodge, J., Kajtar, L., Duxbury, R., Hall, D., Burley, G. A., Cordy, J. M., Yates, J. W. T., & Rattray, Z. (2025) · mAbs · doi:10.1080/19420862.2025.2459795 · Cited by 27
Evolution of the glucagon-like system across fish
Cardoso, J. C. R., Félix, R. C., da Costa, C. K., Palma, P. S., Canário, A. V. M., & Power, D. M. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.10.003 · Cited by 18
Cacciatori, V., Zoppini, G., Bellavere, F., Rigolon, R., Thomaseth, K., Pichiri, I., Trombetta, M., Dauriz, M., De Santi, F., Targher, G., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00300 · Cited by 18
The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight
Hinrichs, G. R., Hovind, P. H., & Asmar, A. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00476.2023 · Cited by 24
Scavo, M. P., Lisco, G., Depalo, N., Rizzi, F. R., Volpe, S., Arrè, V., Carrieri, L., Notarnicola, M., Nunzio, V. D., Curri, M. L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031493 · Cited by 19
“The low levels of hepatic GLP-1 receptors detected in some studies could reflect the presence of the GLP-1 receptor in non-hepatocyte cells, such as immune cells, satellite cells, or blood vessels [25,26,29].”
BackgroundResultXie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Gad, A. I., Ibrahim, N. F., Almadani, N. A., Mahfouz, R., Nofal, H. A. E., Elrafey, D. S., Ali, H. T., Elhawary, A. T., & Sadek, A. M. E. M. (2024) · Diseases · doi:10.3390/diseases12080186 · Cited by 24
“So the changes in hepatic fat are believed to be mediated through changes in metabolic and weight-reduction actions [14,38,39].”
BackgroundBerclaz, C., Pache, C., Bouwens, A., Szlag, D., Lopez, A., Joosten, L., Ekim, S., Brom, M., Gotthardt, M., Grapin‐Botton, A., et al. (2015) · Scientific Reports · doi:10.1038/srep10385 · Cited by 20
Specific biology of neuroendocrine tumors: Peptide receptors as molecular targets
Körner, M. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.01.001 · Cited by 19
Rydén, A., Nyman, G. C., Nalin, L., Andréasson, S., Korsgren, O., Eriksson, O., & Jensen‐Waern, M. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.04.002 · Cited by 21
“[27].”
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 21
Long-acting glucagon-like peptide-1 receptor agonist—status December 2018
Holst, J. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.09 · Cited by 21
“(VIII) The GLP-1R is also heavily expressed on neurons of the enteric nervous system, and this may provide the structural substrate for several both motor and vascular actions locally in the gut, as well as for ascending sensory impulses transmitted to the brain and involved in appetite and glucose control (24).”
BackgroundSafety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
Varin, E. M., McLean, B. A., & Lovshin, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.011 · Cited by 19
Tougaard, R. S., Jorsal, A., Tarnow, L., Hansson, N. H., Kistorp, C., Schou, M., Nielsen, R. R., Flyvbjerg, A., Videbæk, L. M., Mølgaard, H., et al. (2020) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2020.1751873 · Cited by 19
“In the human heart, the GLP-1 receptor is known to be expressed in the SA node [17].”
BackgroundNew Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 21
Antibody Therapies Targeting Complex Membrane Proteins
Salazar, G. T., Huang, Z., Zhang, N., Zhang, X., & An, Z. (2021) · Engineering · doi:10.1016/j.eng.2020.11.013 · Cited by 23
Morrow, N. M., Hanson, A. A., & Mulvihill, E. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703966 · Cited by 19
“A well-validated antibody to the GLP-1R (MAb 3F52) and corroborated with 125I-labeled GLP1 also demonstrated a strong signal in stomach parietal cells, basolateral epithelial cells in the duodenum, Brunner’s glands and the myenteric nerve plexus (Pyke et al., 2014).”
ResultBoulmpou, A., Patoulias, D., Papadopoulos, C. E., Teperikidis, E., Doumas, M. N., & Vassilikos, V. P. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2087839 · Cited by 19
“To date, a series of laboratory studies on diabetic animal models examining the potential antiarrhythmic action of GLP1-RAs have already been published, while intensive research is being conducted with the aim of providing insight on the exact underlying mechanisms [15,25].”
BackgroundTargeting Glomerular Hemodynamics for Kidney Protection
Savedchuk, S., Phachu, D., Shankar, M., Sparks, M. A., & Harrison‐Bernard, L. M. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2022.12.003 · Cited by 18
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y., & Xu, A. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 21
“However, subsequent studies using a highly speci fi c anti-GLP-1R monoclonal antibody showed that GLP-1R expression was virtually undetectable in primate liver [89].”
BackgroundCardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D. J., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17
“Recent findings of GLP-1R expression in monkey and human brain [39, 40] highlight the potential relevance of such central effects that should be further explored.”
Lehtonen, J., Schäffer, L., Rasch, M. G., Hecksher-Sørensen, J., & Ahnfelt-Rønne, J. (2015) · Islets · doi:10.1080/19382014.2015.1137415 · Cited by 17
Bremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 20
“Thus, there are numerous receptors for GLP-1 in the enteric nervous system, particularly in the enteric ganglia (Pyke et al. 2014), and although the intestinal motor functions of the hormone are probably predominantly inhibitory (Tolessa et al.”
BackgroundInfluentialOkubo, H., Kushiyama, A., Nakatsu, Y., Yamamotoya, T., Matsunaga, Y., Fujishiro, M., Sakoda, H., Ohno, H., Yoneda, M., & Asano, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103064 · Cited by 23
Nyström, T., Santos‐Pardo, I., Fang, X. L., Cao, Y., Hedberg, F., & JENDLE, J. H. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.58 · Cited by 17
Khera, E., Zhang, L., Roberts, S. S., Nessler, I., Sandoval, D. A., Reiner, T., & Thurber, G. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224881 · Cited by 18
“Promisingly, endocrine-to-exocrine expression appears similar between mice and humans (ex vivo isletto-exocrine ratio of ;2–7 in humans (9,11,19), ;3 in mice (35), ;5 in monkeys (13), and .”
BackgroundActivation of the renal GLP‐1R leads to expression of Ren1 in the renal vascular tree
Bjørnholm, K. D., Ougaard, M. E., Skovsted, G. F., Knudsen, L. B., & Pyke, C. (2021) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.234 · Cited by 16
Self-citationPatient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16
Localized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication
Tong, J. C. L., Frazer-Morris, C., Shilleh, A. H., Viloria, K., de Bray, A., Nair, A. M., Johnson, P., Spiers, R. M., Kobiita, A., Olaniru, O. E., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.009 · Cited by 25
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
“In human tissues, GLP-1R mRNA expression has been observed in atrial and ventricular cardiomyocytes [21] as well as in the sinoatrial node [25].”
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
“, 2008), current evidence overall suggests that the receptor in humans is expressed predominantly in the sinoatrial node (Pyke et al., 2014; Richards et al., 2014).”
BackgroundBell, D. S. H., & Jerkins, T. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15559 · Cited by 17
Khalid, S. I., Massaad, E., Thomson, K. B., & Shin, J. H. (2024) · Journal of Neurosurgery Spine · doi:10.3171/2024.6.spine24141 · Cited by 25
Njei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · Cureus · doi:10.7759/cureus.71366 · Cited by 30
“Despite conflicting results in the literature, recent evidence may suggest that hepatocytes lack direct GLP-1 receptors [22-24].”
ResultWill GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
Wołos-Kłosowicz, K., Matuszewski, W., Rutkowska, J., Krankowska, K., & Bandurska-Stankiewicz, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206183 · Cited by 19
“However, GLP-1 effects are not limited to glycemia, since GLP-1 receptors are widely distributed in other tissues, including the kidneys, cardiovascular system, central nervous system and gastrointestinal tract [16].”
BackgroundNo QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Demmel, V., Sandberg-Schaal, A., Jacobsen, J. B., Golor, G., Pettersson, J., & Flint, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0442-0 · Cited by 16
“GLP-1 receptors can be found on the sinoatrial node [32], and GLP-1RAs may increase the HR not only through persistent, relative sympathetic enhancements but also by direct sinoatrial node stimulation [33].”
BackgroundCardiovascular Effects of Liraglutide
Mikhail, N. E. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180507152620 · Cited by 17
Cardiometabolic crosstalk in obesity-associated arterial hypertension
Jordan, J., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9348-1 · Cited by 20
“[136] However, recent findings suggest that GLP-1 mediated increases in heart rate may result from direct GLP1 receptor stimulation in cardiac atria rather than changes in cardiac sympathetic control.[137, 138] Overall, several therapeutic approaches that have been specifically developed for cardiovascular or therapeu…”
BackgroundIncretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Wu, W., Wang, Y., Shao, X., Huang, S., Wang, J., Zhou, S., Liu, H., Lin, Y., & Yu, P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314628 · Cited by 17
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging
Zhang, L., & Thurber, G. M. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0880-2 · Cited by 15
“In the pancreas, GLP-1R is weakly expressed in acinar cells of the exocrine pancreas whereas endocrine expression dominates [57,58].”
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117916 · Cited by 15
Sridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 25
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
“Decreased urine albumin excretion may be because of direct GLP-1 effects in the human kidney, including the afferent arteriole.(154,159) This is thought to be independent of natriuresis and tubuloglomerular feedback, though GLP-1RA may also induce natriuresis by acutely inhibiting the sodium hydrogen antiporter NHE3 i…”
BackgroundZhang, C., Barkholt, P., Nielsen, J. C., Thorbek, D. D., Rigbolt, K. T. G., Vrang, N., Woldbye, D. P. D., & Jelsing, J. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146538 · Cited by 18
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Wong, C. K., Yusta, B., Tong, J. C. L., Broichhagen, J., Hodson, D. J., & Drucker, D. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.012 · Cited by 14
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
An Updated Perspective on the Dual-Track Model of Enterocyte Fat Metabolism
Cook, J. R., Kohan, A. B., & Haeusler, R. A. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100278 · Cited by 15
“enterocytes do not express GLP receptors (56, 58), these”
BackgroundGuo, J., Chen, X., Wang, C., Ruan, F., Xiong, Y., Wang, L., Abdel-Razek, O. A., Meng, Q., Shahbazov, R., Cooney, R. N., et al. (2023) · Shock · doi:10.1097/shk.0000000000002285 · Cited by 17
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
Feng, J. N., & Jin, T. (2024) · Medical Review · doi:10.1515/mr-2024-0018 · Cited by 18
“Certain relatively reliable GLP-1R antibodies (3F52 for humans and 7F38 for mice) have been generated by Knud-sen ’ s team, which can be utilized in the detection of GLP-1R expression by immunohistochemistry (IHC) [85, 86].”
BackgroundPATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, K. N., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0457 · Cited by 15
“However, presence of hepatic GLP-1R in hamsters and humans is not yet fully established (Taher et al. 2014; Pyke et al. 2014).”
BackgroundCombining incretin-based drugs and RAAS inhibitors: more cons than pros?
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Raalte, D. H., & Diamant, M. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70167-6 · Cited by 14
Hamamatsu, K., Fujimoto, H., Fujita, N., Murakami, T., Kimura, H., Saji, H., & Inagaki, N. (2018) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2018.06.002 · Cited by 14
Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
LIANG, R., Wang, M., Fu, C. L., Liang, H., Deng, H., Tan, Y. C. R. S., Xu, F. L., & Cai, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0294 · Cited by 14
“GLP-1 receptor is found in various locations such as preglomerular vascular smooth muscle, mesangial cells, and proximal tubular cells in the kidney [9-11].”
BackgroundBeta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
Demine, S., Schulte, M. I., Territo, P. R., & Eizirik, D. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197274 · Cited by 15
“Low levels of expression were also found in other pancreas-surrounding tissues such as the intestine, stomach, lung, and kidneys [67,68], which could increase the background signal; 2.”
BackgroundFernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
Model, J. F. A., Rocha, D. S., Fagundes, A. D. C., & Vinagre, A. S. (2022) · Veterinary and Animal Science · doi:10.1016/j.vas.2022.100245 · Cited by 18
Yang, Y., He, L., Liu, P., Wang, J., Yang, N., Li, Z., Ping, F., Xu, L., Li, W., Zhang, H., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15342 · Cited by 12
“39,40 Another possible mechanism is the fact that GLP-1 directly activates a downstream molecular pathway, cAMP/PKA, which is also activated in the presence of sympathetic overdrive.”
BackgroundThe Thyroid Pathologist Meets Therapeutic Pharmacology
Sande, C. M., Resta, I. T., & LiVolsi, V. A. (2023) · Endocrine Pathology · doi:10.1007/s12022-023-09749-1 · Cited by 15
“In humans, GLP-1 receptors are located on pancreatic β-cells, arterial smooth muscle cells in the kidneys and lungs, and in Brunner’s glands in the duodenum [51].”
BackgroundRiemma, M. A., Mele, E., Donniacuo, M., Telesca, M., Bellocchio, G., Castaldo, G., Rossi, F., Angelis, A. D., Cappetta, D., Urbanek, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422740 · Cited by 15
Nakhleh, A., Shehadeh, N., & Mansour, B. (2024) · Pituitary · doi:10.1007/s11102-024-01451-7 · Cited by 15
“The GLP-1 receptor is expressed in various renal locations, including preglomerular vascular smooth muscle cells and juxtaglomerular cells [8].”
BackgroundCharacterization and Role of Glucagon-Like Peptide 1 Receptor in the Lacrimal Gland
Sun, Y., Zhang, Y., Shi, F., Li, Y., Wang, C., Yu, F., Chen, T., Xia, D., Xu, Y., Zhao, Y., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.12.003 · Cited by 13
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.